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Abstract: The pain relief capabilities of methyl salicylate are well established and a multitude of
over-the-counter products populate pharmacy shelves. Over-application of the topical preparation
containing the drug, or its accidental ingestion, invariably result in salicylate poisoning and in severe
cases can be fatal. The drug has been a regular feature of the US National Poison Database Survey
over the past decade and continues to pose a risk to children and adults alike. The aim of the
review has been to cast a spotlight on the drug and assess why its use remains problematic, how
technology could offer more efficacious delivery regimes, and minimise the possibility of accidental
or intentional misuse.
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1. Introduction
It has become common practice for patients suffering from musculoskeletal injuries or disease to
seek non-prescription medicines in an attempt to minimise pain and ease their condition [1–3]. Recent
estimates suggest that those suffering from acute or chronic pain in the US number in the hundreds of
millions [3] but, while some 10% of all Americans report suffering from chronic pain, the incidence
increases to 60% when considering those aged 65 years or older [4]. Chronic pain can have a pernicious
toll on quality of life and will affect both everyday family activities and workplace responsibilities,
and it is one of the main causes of physical disability in the US [5]. Although the true impact may be
impossible to quantify, some estimates place the annual socio-economic burden experienced by US
citizens alone in the range of $600 billion [6]. Conventional treatment options for those with chronic
musculoskeletal pain are nonsteroidal anti-inflammatory drugs (NSAIDS), opioids, or surgery which,
in many cases, often fail to provide long-term benefit [7–9]. As a result, many will seek alternative
treatments and it is little surprise to find, therefore, that there is a burgeoning market (valued at over
$100 billion per annum (p.a.)) in the supply of non-prescription over-the-counter (OTC) products that
purport to provide a wealth of therapeutic benefits [2].
The latter typically result from the formulation of either single entity or drug combinations that
can impart a local analgesic, anaesthetic, antipruritic, or counterirritant action [10]. The ingredients
can be derived from natural sources or through industrial synthesis and are incorporated into a
diverse range of forms such as pills, gels, ointments, lotions, sprays and, more recently, dressings and
transdermal patches [10,11]. The fact that these products can be readily acquired from sources that offer
no qualified advice beyond the packaging instruction can, however, create issues over their efficacious
application [12]. As such, the potential for misuse, accidental or deliberate, can be significant and is
evidenced in the annual reports arising from the US National Poison Data System (NPDS) [13–18].
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Salicylates feature regularly in the latter, as indicated in Figure 1, and although their therapeutic
properties have long been recognised, the delivery methods have changed little since their discovery.
The aim of the present communication is to explore new developments in the smart administration of
topical agents. The principal focus is on methyl salicylate, given its prominence in the NPDS database,
and although the specifics of the technological options are discussed relative to it, they are often generic
and applicable across a spectrum of therapeutic agents.
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2. Historical Perspective 
Methyl salicylate (MS) is a common, yet complex, signalling molecule used by a host of plant 
and tree species which can warn neighbours of herbivorous insect infestation thereby enabling the 
biochemical upregulation of defences  and  the  recruitment of  the  insect’s predators  [19]. A more 
common association within the wider public arena or among the wider public, however, relates to its 
use as an essential oil, fragrance, and medicinal compound [20]. Historically, it was extracted from 
the small wintergreen plant (Gaultheria procumbens L.), from which it gets its common name, and from 
birch trees (Betula lenta L.) [21]. The leaves and bark from the latter were used by indigenous peoples 
across America and Canada as the basis of herbal infusions for the treatment of rheumatism, fever, 
and gastrointestinal ailments not to mention as a topical agent for burns, wounds, and bruises [22]. 
The analysis of birch leaves reveal that they contain between 0.23–0.6% w/w of essential oil of which 
99.8%  is MS and, hence, provides some evidential weight  to  the professed analgesic properties of 
folklore remedies [22,23].   
3. Commercial Application 
The  action  of  MS  is  multimodal  with  analgesic,  anti‐inflammatory  and 
rubefacient/counterirritant  properties.  The  former  arises  from  the  rapid  hydrolysis  of  the  ester 
yielding salicylic acid as the active agent [24–26] and, as such, its analgesic action is beyond question. 
It has  a vasodilatory  action upon  absorption  resulting  in  an  increased  localised blood  flow  and, 
consequently, produces a rise in tissue temperature—its rubefacient action [27]. Menthol, in contrast, 
has a cooling effect [28] and, thus, their dual incorporation can set up a counterirritant action [29]. 
The therapeutic efficacy of the latter is, however, more contentious, with the UK National Institutes 
for Clinical Excellence (NICE) reporting that there is no clinical evidence to support its use as such 
[30]. Similarly,  the US FDA, with  the exception of Salonpas patches®, has noted  that  there exists 
inadequate data to enable the recognition of effectiveness of such products for the specified OTC uses 
[30,31]. Nevertheless, MS has made the  journey from herbal recipe to mainstream pharmaceutical, 
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exception of Salonpas patches®, has noted that there exists inadequate data to enable the recognition
of effectiveness of such products for the specified OTC uses [30,31]. Nevertheless, MS has made the
journey from herbal recipe to mainstream pharmaceutical, with synthetic manufacturing processes
accounting for almost all modern-day formulations. While there are a multitude of pseudo-medicinal
products in which MS is listed as the active agent, it must be recognised that it is also employed as
a flavour and fragrance enhancer. The compound gives a sweet, mint-like odour and is frequently
incorporated into breath mints and chewing gum and, given that it possesses some intrinsic antiseptic
properties [32], has found use in toothpastes and mouthwashes. However, its use is much more
pervasive with the “fresh” fragrance being employed in a range of common household disinfectants.
The breadth of cosmetic products in which MS features is highlighted in Table 1, along with some of
the typical concentrations disclosed to the US Food and Drug Administration database.
Table 1. Prevalence of methyl salicylate in consumer products.
Cosmetic Category FDA Products Conc. of MS %
Dentifrices 38 0.03
Mouthwashes and breath fresheners 49 0.08–0.2
Other oral hygiene products 6 0.2
Bath soaps and detergents 385 0.0001
Bath oils, tablets, and salts 124 —
Body and hand preparations 796 0.05
Skin cleansing 653 —
Douches 5 —
Foot powders and sprays 35 0.02
Hair conditioners 636 —
Shampoos 860 —
Tonics, dressings, hair-grooming aids 549 —
Paste masks 255 0.6
Skin fresheners 184 0.1
Other skin care preparations 692 0.02
Suntan gels, creams, and lotions 136 0.2
The concentrations of MS in standard cosmetic products tends to be very low, but can increase
dramatically when considering preparations designated for therapeutic use. Aromatherapy is a
prime example where oil of wintergreen is essentially 98% MS [22,23,33]. On the assumption that
the practitioner is appropriately skilled and following their working codex, the wintergreen oils
will normally be blended with other “base” oils such that the overall concentration falls within
0.5–5% [34,35]. Massage OTC products (typically in the form of liniments, creams, and dressings)
utilise the anti-inflammatory properties of MS and, where once the preserve of those engaged in
sport, are increasingly being marketed to those suffering from joint and muscle pains originating
from rheumatic conditions [36]. These products, designed for topical application, typically have
MS concentrations in the region of 3–20% and can come with minimal instruction or advice. Any
drug product containing salicylates intended for oral ingestion must be appropriately labelled with a
warning that misdirected use may be dangerous and that it must be kept out of the reach of children.
The same only applies to topical MS products where the concentration of the latter exceeds 5% [37].
4. Transdermal Biochemistry
Oral NSAIDs are commonly used to treat musculoskeletal pain, but repeated administration in
chronic conditions can give rise to a number of adverse effect profiles [38]. Topical administration has
garnered considerable interest in recent years as the delivery mechanism provides a clear opportunity
to avoid the complications of oral intake and, in particular, gastric irritation. The key requirement,
however, is that the NSAID can sufficiently penetrate the skin and, therein, reach the affected site.
There can be a degree of ambiguity over the mode of action relating to whether the clinical outcome
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arises from the direct translation of the drug locally to the affected tissue or whether it is the result
of systemic absorption and subsequent redistribution [39]. The latter can only occur where there the
drug can pass across the top layers of the skins (stratum corneum, viable epidermis, and basement
layer) to reach the dermis which contains the blood vessels necessary for transport into the deeper
tissues [24,40].
Methyl salicylate is lipophilic and when applied as a topical agent has been shown to readily
penetrate the skin and is readily hydrolysed to salicylic acid in the tissues [41–48]. Yano and colleagues
(1991), however, demonstrated that menthol and camphor, added as co-drugs, significantly inhibit the
esterase activity in a dose-dependent manner and, consequently, many of the topical massage products
utilise these agents in their formulation [43]. Once absorbed, the resulting salicylate is distributed
throughout the tissues and transcellular fluids, primarily through passive pH-dependent processes.
It has been estimated that the plasma half-life for salicylate is 2 to 3 h in low doses, increasing to 12 h at
usual anti-inflammatory doses. In cases where supratherapeutic doses/salicylate intoxication occurs,
the half-life may be as much as 15 to 20 h [48]. Under normal therapeutic regimes, conjugation with
glycine to form salicyluric acid and with glucuronic acid to form salicyl acyl and phenolic glucuronide
are the major metabolic/excretion pathways as outlined in Figure 2. Oxidation of the salicylate to
gentisic acid (2,5-dihydroxybenzoic acid), 2,3-dihydroxybenzoic and 2,3,5-trihydroxybenzoic acids can
also occur, but are minor in comparison to the other routes [48]. The metabolites are readily excreted
in the urine with the free unmodified salicylate accounting for 10–30%. The latter can rise significantly
at large therapeutic loadings as both the glycine and glucuronide pathways have limited capacity
and saturate easily [48]. As a result, the tissues become saturated and chronic salicylate toxicity can
occur—hence, the prolonged half-life.
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volunteers was performed by Morra and colleagues (1996) [42]. An ointment containing 12.5% MS 
was applied to twelve volunteers (six male, six female) twice daily over a period of four days and the 
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Figure 2. Metabolites of salicylic acid (SA); SPG: salicylic acid phenolic glucuronide; SAG: salicylic
acid acyl glucuronide; SU: salicyluric acid; GA: gentisic acid; GU: Gentisuric acid [49,50].
One of the more recent studies examining the transdermal influence of MS application in human
volunteers was performed by Morra and colleagues (1996) [42]. An ointment containing 12.5% MS
was applied to twelve volunteers (six male, six female) twice daily over a period of four days and
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the salicylate concentrations within serum analysed prior to dosing and at various intervals between
subsequent applications. Urine was also collected during the entire study. While salicylate was found
within the serum, at no point was unchanged MS detected, despite its relatively high loading within
the ointment—confirming its rapid hydrolysis upon absorption. Serum salicylate concentrations
ranged from 0.3–0.9 mg/L within the first hour of application and increased to 2–6 mg/L by day 4.
Salicylic acid, along with its uric acid (SU) conjugates, were detected in the urine at concentrations
of 15.6 and 491.9 mg/L, respectively. The relative proportions of the various metabolites in urine
can be highly variable and dependent on both therapeutic dose and pH. The typical compositional
breakdown under moderate doses yields: free salicylic acid (10%), salicyluric acid (75%), salicylic
phenolic glucuronide (10%), salicylic acyl glucuronides 5%), and gentisic acid (less than 1%). Gilman
(1990), however, demonstrated that under acid or alkaline conditions—the recovery of free salicylic
acid could drift between 2 and 30% of the ingested drug [47]. The recovery of total salicylic acid
over days 1–4 was 15.5, 22.0, 22.4, and 22.2%, respectively [42]. In humans, it has been estimated that
12–20% of MS applied topically is directly absorbed within the first 10 h, but it is important to note
that the composition of the actual product (ethanol, isopropanol, menthol, camphor, etc.) along with
the condition of the skin can greatly influence the transport and hydrolysis kinetics [42].
5. Accidental/Intentional Misuse
The ubiquity of salicylates in over-the-counter (OTC) topical pain medications has long given
rise to concerns over their potential for misuse and accidental poisoning [51,52]. The high morbidity
and mortality of paediatric referrals after ingestion of preparations containing oil of wintergreen has
been of particular importance as, in its freshly distilled form, it contains over 98% MS [52–56]. It is
widely established that the ingestion of a single teaspoon (~5 mL) of the oil, whether synthetic or
natural, can be equivalent to almost 22 conventional aspirin tablets giving rise to a potentially acute
toxic dose of salicylate [51]. Fortunately, the incidence of referrals due to MS has been in decline in
recent years (Figure 1) with the overall fall being indicative of increasing numbers of alternatives, such
as diclofenac and ibuprofen-based preparations. It is important to note that case reports involving MS,
as a percentage of all issues involving topical agents, has stayed relatively constant at 10–11% over the
past decade [13–18].
It must be acknowledged that the OTC status of many products containing MS can lead
to the erroneous assumption that they are inherently safe, thereby leading to unintentional
poisoning [56,57]. The latter is highlighted by the recent death of a seventeen-year-old cross-country
runner after excessive self-administration of a topical muscle-pain relief treatment incorporating
MS [58]. It has been estimated that over 25% of US parents have poor health literacy skills and there is
little doubt that this will be a factor in some of these incidents—especially where administration and
dosing will largely be done by the parent without medical consultation [57]. The American Association
of Poison Control Centres Toxic Exposure Surveillance System (AAPCC-TESS) has reported that about
77% of the enquiries relating to exposures/incidents of MS poisoning involve children under six years
of age [13–18].
Pharmaceutical preparations are not, however, the only source and there is increasing
apprehension over the use of “natural” remedies involving various leaf and bark infusions [57,59,60].
Birch or wintergreen extracts, especially when distilled into the oil, were historically the principal
source of MS and are little different from the synthetic “wintergreen” products available in any
pharmacy. Infusions into hot water will yield the characteristic wintergreen aroma [22]. The sweet,
distinctive aroma can too easily be associated with its use as a flavouring agent in confectionary [32],
thereby reinforcing the perception that the substance is inherently safe to use. Moreover, the “age
old” connotations ascribed to many of the formulations are often viewed as a safer, holistic alternative
to modern drugs with consumer awareness benefiting from the proliferation of internet testimonials
of the potential therapeutic benefit. Herbal supplements are an increasingly important contributor
to OTC sales in western countries with year-on-year growth (6.8% in the US from 2013 to 2014)
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and it has been suggested that they are particularly significant among paediatric and adolescent
populations [6,59,60]. Recent surveys revealed that between 0 and 17 years of age, the administration
of herbal remedies in Germany and the US were relatively similar with 6% and 4%, respectively [59,60].
This increased public interest in traditional and herbal remedies now poses a significant concern as
they invariably lack the conspicuous warnings and directions mandated for conventional product
labelling [56–58]. While the need to provide clear, consistent, and standardized label information to
support consumer comprehension has long been recognised for pharmaceutical products, the potency
of natural components can be highly variable and efficacy will be highly dependent on the morphology,
age, and quantity of the ingredients used. There can be a dearth of information on the safety of local (or
internet) preparations where recipes are invariably vague. Casual inspection of web sites demonstrates
an uncomfortably relaxed approach to hazard labelling. In many cases, the information presented
invariably extols the virtues of the natural remedy without providing adequate caution as to the
potential adverse health implications.
6. Technological Solutions
A prime issue in the adoption of topical MS products relates to the user administration of liquid
formulations. While the instructions will invariably caution against over-application to the skin
or direct ingestion, there is no physical barrier preventing either occurring should the user wish.
Incorporation of MS in a patch or dressing is, however, an approach that mitigates against wilful
misuse or inappropriate overuse and can effectively eliminate the possibility of accidental ingestion
by children—historically a critical failing of wintergreen medicants [51–57]. There are a number of
commercial forms that effectively lock the MS and co-drugs (such as menthol) within a framework
that only permits transfer through transdermal contact. Passive diffusion of the therapeutic agents
across the skin barrier can typically occur over a period of hours and they are invariably marketed
as providing “long-lasting” pain relief. Such systems can vary in complexity from the agent being
dissolved in adhesive binders that can be directly applied to the skin through to multilayer assemblies
encapsulating a range of chemical components [61]. The latter can have profound impact on the
performance of the patch and can include components that affect the transfer of the drug (permeation
enhancers, rate controlling membranes, solubilizers), as well as enabling the design conformity of the
device (adhesives, tackifiers, plasticisers) [61].
There remains considerable research into the design of supramolecular gelation layers than can
encapsulate salicylates—and MS, in particular, with the aim of enhancing the biocompatibility of the
host matrix and enabling more controllable release of the therapeutic agent [62–64]. While there are
numerous formulations available, it is important to note that very few have been approved by the
FDA for the temporary relief of pain relative to the many conditions associated with chronic pain, as
indicated in Table 2.
Table 2. FDA approved transdermal patches for pain relief.
Year Drug Product Application
1990 Fentanyl Duragesic Chronic pain
1995
Epinephrine; Lidocaine
HCl Iontocaine Local dermal analgesia
2005 Lidocaine; Tetracaine Synera Local dermal analgesia
2007 Diclofenac Epolamine Flector Nonsteroidal anti-inflammatory
2008
Menthol; Methyl
Salicylate Salonpas Topical analgesic
2010 Buprenorphine Butrans Chronic pain
2013 Sumatriptan Succinate Zecuity Acute migraine pain
The transdermal patches are generally considered to be first generation “devices” and almost
invariably rely on the lipophilic properties of the drug to pass across the stratum corneum [65–68].
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Although this action requires no additional input from the patient, it also means that there is no
mechanism for modifying the rate at which the dose is delivered once the patch has been positioned.
The main benefit of the patch system, however, is that it is effectively a “metered” dose, unlike the
ointments, gels or liquids whose volume (and hence dose) depends principally on the judgement of
the user.
Although the drug delivery profile can, in principle, be controlled through the design of the patch
structure, the rate of release can be further influenced by changes in ambient or local heat [66,68].
Elevated temperatures can accelerate the delivery of the drug but, in doing so, may also subsequently
decrease the transfer rate once the heat source is removed—as a consequence of the load being
prematurely depleted. The efficacy of the delivery can, therefore, be affected where such patches are
intended to be applied over extended durations and where a suboptimal delivery arises in the later
stages. Such profiles have been corroborated through a number of in vivo studies of patches containing
methylphenidate [65], buprenorphine [66], and fentanyl [67,68]. The rate and extent of drug release,
although dependent on drug formulation and patch design has, nevertheless, been shown to increase
significantly upon the addition of heat. In the cases of buprenorphine and fentanyl, the addition of a
heat pad led to plasma levels increasing by up to 55% and 61%, respectively [66,68].
6.1. Iontophoretic Delivery Options
The ability of small, neutral compounds to permeate the skin barrier has long been recognised
and exploited, but the application of electrical current (iontophoresis), ultrasound (sonophoresis), or
microneedle methods can provide options for enhancing the transfer [69–79]. Iontophoresis essentially
employs a DC current to drive drugs across the stratum corneum, rather than provoke any significant
disruption of the skin’s structure as indicated in Figure 3. These approaches are well established
and there is an extensive literature available on their application to a wide spectrum of drugs and
salicylates. A two-electrode system is almost invariably employed and placed directly on the skin
surface as indicated in Figure 3. The “delivery” reservoir typically contains drugs bearing a charge
similar to the polarity imposed at that electrode. The counter electrode completes the circuit and when
the current is applied, ions migrate (driven) from the delivery side through the skin bridge, due to the
electric field, with counter ions (ions of opposite polarity such as Na+ or Cl−) moving to restore charge
balance. The efficiency of iontophoretic transport (ratio of current carried by the drug and the total
current applied across the membrane) is usually low because of competition from a large pool of ions
already present within the tissue and the relatively low electromobility of the target drug compared to
the latter.
Medicines 2017, 4, 48  7 of 13 
 
patches are intended to be applied over extended durations and where a suboptimal delivery arises 
in  the  later  stages. Such profiles have been  corroborated  through a number of  in vivo  studies of 
patches  containing methylphenidate  [65], buprenorphine  [66],  and  fentanyl  [67,68]. The  rate  and 
extent of drug release, although dependent on drug formulation and patch design has, nevertheless, 
been shown to increase significantly upon the addition of heat. In the cases of buprenorphine and 
fentanyl, the addition of a heat pad led to plasma levels increasing by up to 55% and 61%, respectively 
[66,68].   
6.1. Iontophoretic Delivery Options 
The ability of small, neutral compounds to permeate the skin barrier has long been recognised 
and exploited, but the application of electrical current (iontophoresis), ultrasound (sonophoresis), or 
microneedle  methods  can  provide  options  for  enhancing  the  transfer  [69–79].  Iontophoresis 
essentially employs a DC current to drive drugs across the stratum corneum, rather than provoke 
any significant disruption of the skin’s structure as indicated in Figure 3. These approaches are well 
established and there is an extensive literature available on their application to a wide spectrum of 
drugs and salicylates. A two‐electrode system is almost invariably employed and placed directly on 
the skin surface as indicated in Figure 3. The “delivery” reservoir typically contains drugs bearing a 
charge similar to the polarity imposed at that electrode. The counter electrode completes the circuit 
and when the current is applied, ions migrate (driven) from the delivery side through the skin bridge, 
due to the electric field, with counter ions (ions of opposite polarity such as Na+ or Cl−) moving to 
restore charge balance. The efficiency of iontophoretic transport (ratio of current carried by the drug 
and  the  total current applied across  the membrane)  is usually  low because of competition  from a 
large pool of ions already present within the tissue and the relatively low electromobility of the target 
drug compared to the latter. 
 
Figure 3. Electromigration during iontophoretic drug delivery. 
It has been shown that, with negatively‐charged species, less than 20% of the current is carried 
by the compound [69–71]. Nevertheless, numerous studies have demonstrated the effectiveness of 
iontophoresis for enhancing the transport of salicylate [72,73], and there has been extensive research 
into  minimising  the  effect  of  endogenous  ion  competition.  The  introduction  of  ion  exchange 
membranes  and  drug  carriers  such  as  liposomes  [74,75]  microemulsions  [76],  polymeric 
nanoparticles [77], and solid liquid nanoparticles have all been investigated in order to enhance the 
drug transfer. The use of iontophoresis with lipid nanoparticles loaded with salicylic acid was shown 
to significantly improve the amounts delivered across human epidermal membranes in comparison 
to passive transfer—even when the latter was continued for four times the duration. Crucially, it has 
been  shown  that  when  applied  to  Wistar  rats,  the  excised  skin  revealed  that  the  salicylate 
concentration was greater  in  the  skin  and  subcutaneous  tissues directly below  the  iontophoresis 
delivery site than in the plasma, suggesting that the mode of action is local [78,79]. 
Figure 3. Electromigration during iontophoretic drug delivery.
Medicines 2017, 4, 48 8 of 13
It has been shown that, with negatively-charged species, less than 20% of the current is carried
by the compound [69–71]. Nevertheless, numerous studies have demonstrated the effectiveness of
iontophoresis for enhancing the transport of salicylate [72,73], and there has been extensive research
into minimising the effect of endogenous ion competition. The introduction of ion exchange membranes
and drug carriers such as liposomes [74,75] microemulsions [76], polymeric nanoparticles [77], and
solid liquid nanoparticles have all been investigated in order to enhance the drug transfer. The use of
iontophoresis with lipid nanoparticles loaded with salicylic acid was shown to significantly improve
the amounts delivered across human epidermal membranes in comparison to passive transfer—even
when the latter was continued for four times the duration. Crucially, it has been shown that when
applied to Wistar rats, the excised skin revealed that the salicylate concentration was greater in the skin
and subcutaneous tissues directly below the iontophoresis delivery site than in the plasma, suggesting
that the mode of action is local [78,79].
While there has been extensive investigation of iontophoretic salicylic acid transfer, methyl
salicylate has received considerably less attention. The lipophilic properties of the ester and its ready
absorption through the skin, in comparison to salicylic acid, has meant that there has been little need to
drive its transfer. Nevertheless, Wani and Gaikwad (2013) investigated the effectiveness of employing
iontophoresis in the delivery of MS to patients suffering with knee osteoarthritis (KOA) [80]. The
patients were assessed for pain and functional capacity using the numerical pain rating scale (NPRS),
walking speed test (WST), modified get up and go test (MGUGT), total single limb standing test
(TSLST), and Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) before and after
two weeks of intervention. In comparison to a control group (receiving only a moist pack), significant
improvements in all, except the MGUGT, scores were observed, suggesting that the approach was
effective in enhancing pain relief and functional capability [80].
Leaving aside the therapeutic efficacy, the key benefit of iontophoresis on MS administration
relates to the fact that it provides a mechanism through which the delivery rate may be controlled to a
high degree of specificity. Due to the direct relationship between the applied current and transdermal
flux, iontophoresis embodies the intrinsic ability to regulate or inhibit the delivery rate over a given
period of time. Rate control may be devolved to the responsibility of the patient or, more ideally,
controlled by incorporation of a microprocessor, thereby enabling complex and bespoke delivery
profiles to be enacted. Given the increasing miniaturisation of electronic systems and integration with
smart devices (phones, watches, and fitness trackers), it could then be expected that the translation
of iontophoretic systems to a more manageable format is likely in the future [81]. The glucose watch,
employing reverse iontophoresis has, in many respects, highlighted how the technology could be
developed with the patient in mind and the need to accommodate everyday activities. While such
devices can never compete with the low-cost disposable patches targeted at acute pain, the increased
control over delivery schedule and potential optimisation of dose could be of significant benefit to
those suffering from chronic conditions. Critically, such technology could ultimately provide the
capability to titrate doses and prevent undesirable fluctuations of drug concentration in the blood,
thus avoiding over-use.
6.2. Microneedle Systems
Microneedle (MN) patch systems have gained considerable interest and the scientific literature
is awash with a multitude of designs covering an equally diverse range of drugs [82–85]. The key
advantage of MN patches, from a drug delivery perspective, relates to their ability to painlessly
breach the skin barrier [82]. As such, they are an ideal conduit for the transfer of agents which would
otherwise have limited ability to absorb passively. There are numerous MN formats and a detailed
description of their properties is beyond the scope of the present discussion. Irrespective of design,
drug loading will be significantly limited in comparison to conventional oral (or intravenous) dosing
and, therefore, they are almost invariably targeted at the delivery of low yield—high potency agents
such as vaccines. There are extensive examples of their use in the delivery of diclofenac [82] but, as yet,
Medicines 2017, 4, 48 9 of 13
no reports of salicylate transfer. The use of diclofenac is noteworthy beyond its use as an NSAID in
that it has been shown to delay the closure of the transdermal channels created by MN patches [82,83].
This can be useful in “poke and patch” scenarios where topical agents applied as a gel or spray after
removal of the MN exploit those channels to reach the dermis [77,78].
Microneedles that dissolve or swell are among the more recent developments within this field
and can offer a means through which to control the rate of delivery. The drug is normally encapsulated
as a composite component along with a structural material necessary to provide the needle framework.
Upon insertion into the skin, the MN framework dissolves at a given rate (determined by the
manipulation of formulation factors during manufacture) and, in doing so, releases the drug [77].
It could be envisaged that this strategy could be adopted for the delivery of salicylates and thereby
offer a metered dose directly to the affected tissue. In the case of methyl salicylate, it does not offer
much of an advance over the conventional passive patches and can still be prone to misuse where the
patient is able to apply multiple patches.
Microneedle technology has been evolving and, just as the passive patches are beginning to
morph into smart systems capable of regulating dose, there is a slow transition from systems designed
purely to ease drug delivery to integrated devices capable of sensor-actuator functions [82]. At present,
the two functions are largely discrete, but it is inevitable that there will be an eventual marriage of
the technology.
7. Conclusions
Transdermal drug delivery can often be regarded as a superior option to other routes of
administration as it offers the prospect of greater control over the dosage. However, this comes
with a multitude of caveats and there is no doubt that in acquiring greater control, the degree of
complexity in the formulation or technological framework is dramatically increased. The development
of smart technologies has gathered considerable pace, and while commercial devices have yet to gain
a foothold, the foundations for their arrival have been laid. The convenience of the OTC passive
patches and the fact that they can be worn, usually in an unobtrusive manner, and will deliver known
amounts of MS over the course of several hours, already provides an excellent solution over the manual
application of a topical gel, spray, or liquid. Upgrading to a wireless system controlled by a phone
app brings further benefits, but it also significantly increases the cost. There may be limited efficacy in
the latter for acute pain but there could be significant benefits in treating chronic pain where local or
systemic concentrations can be regulated with greater precision. Generic iontophoretic patches for
drug delivery are already available and it is inevitable that the software required to enable tailor drug
profiles directed by a smart phone will follow.
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